Table 5. IC₅₀ values (µM) of doxorubicin (DOX) and cisplatin (CIS) alone and in combination with L-canavanine (L-CAV), using non-constant ratio combinations.

N°	Cell	IC50 value of DOX or CIS Alone (IC50 ± SD)	Combination	IC50 value of DOX or CIS in Combination (IC50 ± SD)	CI	Interpretation
1	HeLa	4.07 ± 0.26	IC10 of L-CAV and DOX	0.11 ± 0.03	0.11	Strong synergism
2			IC30 of L-CAV and DOX	0.0043 ± 0.0015	0.38	Synergism
3		54.07 ± 12.25	IC10 of L-CAV and CIS	0.30 ± 0.09	0.09	Very strong synergism
4			IC30 of L-CAV and CIS	0.066 ± 0.02	0.38	Synergism
5	MIA PaCa-2	22.25 ± 3.35	L-CAV IC10 and DOX	2.44 ± 0.28	0.14	Strong synergism
6			L-CAV IC30 and DOX	0.62 ± 0.06	0.27	Strong synergism
7		97.20 ± 20.34	L-CAV IC10 and CIS	88.80 ± 5.44	0.81	Moderate synergism
8			L-CAV IC30 and CIS	14.57 ± 2.85	0.37	Synergism
9	SK-HEP-1	11.09 ± 0.82	L-CAV IC10 and DOX	0.32 ± 0.09	0.28	Strong synergism
10			L-CAV IC30 and DOX	0.31 ± 0.08	0.61	Synergism
11		77.89 ± 17.77	L-CAV IC10 and CIS	20.72 ± 2.16	0.44	Synergism
12			L-CAV IC30 and CIS	4.56 ± 1.31	0.63	Synergism

Note:

Data from three independent experiments (n = 3) are represented as mean ± SD.